<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02784561</url>
  </required_header>
  <id_info>
    <org_study_id>81370666-2</org_study_id>
    <nct_id>NCT02784561</nct_id>
  </id_info>
  <brief_title>Study of Busulfan and FLAG Conditioning Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation</brief_title>
  <official_title>Safety and Efficacy Study of Busulfan/FLAG Conditioning Regimen in Patients With Relapsed/Refractory Acute Leukemia Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>309th Hospital of Chinese People's Liberation Army</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Naval General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Space Center Hospital, Peking University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chinese PLA General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and efficacy of Busulfan/FLAG
      (fludarabine, cytarabine and granulocyte colony-stimulating factor) Conditioning Regimen in
      Patients with Relapsed/refractory Acute Leukemia undergoing allogeneic peripheral blood stem
      cell transplantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Allogeneic hematopoietic stem cell transplantation (allo-SCT) is the only way to cure
      relapsed/refractory acute leukemia. Busulfan/Cyclophosphamide (BuCy, Cytarabine, Busulfan,
      Cyclophosphamide) has been a classical conditioning regimen for allo-SCT. Substitution of
      Cyclophosphamide in the BuCy regimen with Fludarabine (BuF) resulted in reduced toxicity and
      similar efficacy. FLAG (fludarabine, cytarabine and granulocyte colony-stimulating factor) is
      a chemotherapy regimen that has been proved to be effective for relapsed/refractory acute
      leukemia as salvage therapy. To reduce the relapse and improve the survival of those patients
      with relapsed/refractory acute leukemia who receive allo-SCT, the novel conditioning regimen
      consisting of Busulfan/FLAG was developed. The combination of Bu and FLAG without interval
      shortens the duration of conditioning and the pneutropenic period of the patient compared
      with successive administration of FLAG followed with BuF. In addition, regarding the
      established safety and efficacy of BuF and FLAG, it is reasonable to expect similar safety
      and enhanced antileukemic efficacy for Bu/FLAG compared with BuF. In this study, the safety
      and efficacy of this regimen in patients with relapsed/refractory acute leukemia undergoing
      allogeneic peripheral blood stem cell transplantation was investigated.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants relapse as assessed by NCCN (National Comprehensive Cancer Network )criteria</measure>
    <time_frame>two years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of Complete Remission as assessed by NCCN (National Comprehensive Cancer Network )criteria</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DFS(disease-free survival )</measure>
    <time_frame>two years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TRM(treatment-related mortality )</measure>
    <time_frame>two years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with aGVHD as assessed by acute graft versus host disease grading criteria (refer to Glucksberg criteria)</measure>
    <time_frame>three months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with Regimen-related adverse events as assessed by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Leukemia</condition>
  <arm_group>
    <arm_group_label>Busulfan/FLAG conditioning regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All recipients in this arm received the conditioning regimen consisting of Busulfan/FLAG (fludarabine, cytarabine and granulocyte colony-stimulating factor).
The conditioning regimen for peripheral blood stem cell transplantation consisted of busulfan (3.2 mg/kg/ day intravenously [i.v.], days -10 to -8), fludarabine (30 mg/m2, day -7 to -3), cytarabine (1.6 g/m2/day, days
-7 to -3), granulocyte colony-stimulating factor (5 ug/ kg, day -8 to -3). ATG (Thymoglobuline, rabbit) for haploidentical and matched unrelated donors transplantation recipients was used on 2.5 mg/kg/d from days -5 to -2).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan (Zhejiang Otsuka Pharmaceutical Co. Ltd)</intervention_name>
    <description>busulfan (3.2 mg/kg/day intravenously [i.v.], days -10 to -8)</description>
    <arm_group_label>Busulfan/FLAG conditioning regimen</arm_group_label>
    <other_name>Myleran, Busulfex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine(Actavis Italy S.p.A)</intervention_name>
    <description>cytarabine (1.6 g/m2/day, days -7 to -3)</description>
    <arm_group_label>Busulfan/FLAG conditioning regimen</arm_group_label>
    <other_name>Ara-C</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine (Bayer)</intervention_name>
    <description>fludarabine (30 mg/m2, day -7 to -3),</description>
    <arm_group_label>Busulfan/FLAG conditioning regimen</arm_group_label>
    <other_name>fludarabine phosphate (Fludara)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>granulocyte colony-stimulating factor (KirinKunpeng)</intervention_name>
    <description>granulocyte colony-stimulating factor (5 ug/kg, day -8 to granulocyte recovery)</description>
    <arm_group_label>Busulfan/FLAG conditioning regimen</arm_group_label>
    <other_name>G-CSF（granulocyte colony-stimulating factor ）</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rabbit ATG（Sanofi/Genzyme）</intervention_name>
    <description>ATG; thymoglobuline, rabbit;2.5 mg/kg/day, days -5 to -2</description>
    <arm_group_label>Busulfan/FLAG conditioning regimen</arm_group_label>
    <other_name>Thymoglobuline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  relapsed/refractory acute leukemia regardless of cytogenetics

          -  All patients should aged 12 to 65 years

          -  Have matched sibling donors, ≥8/10 HLA(human leukocyte antigen) matched unrelated
             donors or haploidentical donors

          -  Patients without any uncontrolled infections or without severe pulmonary, renal,
             hepatic or cardiac diseases

        Exclusion Criteria:

          -  Patients aged less than 12 years old

          -  Patients with any uncontrolled infections or with severe pulmonary, renal, hepatic or
             cardiac diseases

          -  Acute myeloid leukemia patients with t (15;17)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daihong Liu, Doctor</last_name>
    <role>Study Director</role>
    <affiliation>Chinese PLA General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Daihong Liu, Doctor</last_name>
    <phone>86-13681171597</phone>
    <email>daihongrm@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Liping Dou, Doctor</last_name>
    <phone>86-13681207138</phone>
    <email>lipingruirui@163.com</email>
  </overall_contact_backup>
  <reference>
    <citation>Forman SJ, Rowe JM. The myth of the second remission of acute leukemia in the adult. Blood. 2013 Feb 14;121(7):1077-82. doi: 10.1182/blood-2012-08-234492. Epub 2012 Dec 14. Review.</citation>
    <PMID>23243288</PMID>
  </reference>
  <reference>
    <citation>Tang W, Fan X, Wang L, Hu J. Busulfan and fludarabine conditioning regimen given at hematological nadir of cytoreduction fludarabine, cytarabine, and idarubicin chemotherapy in patients with refractory acute myeloid leukemia undergoing allogeneic stem cell transplantation: a single arm pilot consort study. Medicine (Baltimore). 2015 Apr;94(15):e706. doi: 10.1097/MD.0000000000000706.</citation>
    <PMID>25881847</PMID>
  </reference>
  <reference>
    <citation>Middeke JM, Herbst R, Parmentier S, Bug G, Hänel M, Stuhler G, Schäfer-Eckart K, Rösler W, Klein S, Bethge W, Bitz U, Büttner B, Knoth H, Alakel N, Schaich M, Morgner A, Kramer M, Sockel K, von Bonin M, Stölzel F, Platzbecker U, Röllig C, Thiede C, Ehninger G, Bornhäuser M, Schetelig J. Clofarabine salvage therapy before allogeneic hematopoietic stem cell transplantation in patients with relapsed or refractory AML: results of the BRIDGE trial. Leukemia. 2016 Feb;30(2):261-7. doi: 10.1038/leu.2015.226. Epub 2015 Aug 18.</citation>
    <PMID>26283567</PMID>
  </reference>
  <reference>
    <citation>Fu H, Xu L, Liu D, Zhang X, Liu K, Chen H, Wang Y, Han W, Han T, Huang X. Late-onset hemorrhagic cystitis after haploidentical hematopoietic stem cell transplantation in patients with advanced leukemia: differences in ATG dosage are key. Int J Hematol. 2013 Jul;98(1):89-95. doi: 10.1007/s12185-013-1350-8. Epub 2013 Apr 30.</citation>
    <PMID>23632950</PMID>
  </reference>
  <reference>
    <citation>Wang Y, Liu QF, Xu LP, Liu KY, Zhang XH, Ma X, Fan ZP, Wu DP, Huang XJ. Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study. Blood. 2015 Jun 18;125(25):3956-62. doi: 10.1182/blood-2015-02-627786. Epub 2015 May 4.</citation>
    <PMID>25940714</PMID>
  </reference>
  <reference>
    <citation>Sun Y, Beohou E, Labopin M, Volin L, Milpied N, Yakoub-Agha I, Piemontese S, Polge E, Houhou M, Huang XJ, Mohty M, Nagler A, Gorin NC; Acute Leukemia Working Party of the EBMT. Unmanipulated haploidentical versus matched unrelated donor allogeneic stem cell transplantation in adult patients with acute myelogenous leukemia in first remission: a retrospective pair-matched comparative study of the Beijing approach with the EBMT database. Haematologica. 2016 Aug;101(8):e352-4. doi: 10.3324/haematol.2015.140509. Epub 2016 Apr 14.</citation>
    <PMID>27081180</PMID>
  </reference>
  <reference>
    <citation>Chang YJ, Huang XJ. Haploidentical stem cell transplantation: anti-thymocyte globulin-based experience. Semin Hematol. 2016 Apr;53(2):82-9. doi: 10.1053/j.seminhematol.2016.01.004. Epub 2016 Jan 18. Review.</citation>
    <PMID>27000731</PMID>
  </reference>
  <reference>
    <citation>Wang Y, Wu DP, Liu QF, Qin YZ, Wang JB, Xu LP, Liu YR, Zhu HH, Chen J, Dai M, Huang XJ. In adults with t(8;21)AML, posttransplant RUNX1/RUNX1T1-based MRD monitoring, rather than c-KIT mutations, allows further risk stratification. Blood. 2014 Sep 18;124(12):1880-6.</citation>
    <PMID>25082877</PMID>
  </reference>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 17, 2016</study_first_submitted>
  <study_first_submitted_qc>May 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2016</study_first_posted>
  <last_update_submitted>May 24, 2016</last_update_submitted>
  <last_update_submitted_qc>May 24, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese PLA General Hospital</investigator_affiliation>
    <investigator_full_name>Daihong Liu</investigator_full_name>
    <investigator_title>Head of Hematology departemnt in Chinese PLA General Hospital</investigator_title>
  </responsible_party>
  <keyword>allogeneic peripheral blood stem cell transplantation</keyword>
  <keyword>conditioning regimen</keyword>
  <keyword>acute leukemia</keyword>
  <keyword>relapsed/refractory</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Vidarabine</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

